AbCellera Biologics Reports 38% Revenue Growth in Q3 2025 Despite Net Loss

AbCellera Biologics Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $8.96 million, a 38% increase from $6.51 million in the same period of 2024. For the nine months ending September 30, 2025, revenue rose to $30.28 million, up 27% from $23.78 million in the prior year. The increase in revenue was primarily driven by higher research fees and a notable rise in licensing revenue, which reached $10.75 million compared to just $138,000 in the previous year. However, the company recorded a net loss of $57.12 million for the quarter, compared to a loss of $51.11 million in Q3 2024, reflecting ongoing investments in research and development.

Operating expenses for the third quarter totaled $85.23 million, down from $100.17 million in the same quarter last year. This decrease was largely attributed to a significant reduction in depreciation, amortization, and impairment expenses, which fell from $36.92 million to $5.25 million. Research and development expenses increased by 34% to $55.03 million, driven by investments in internal programs and an increase in headcount. General and administrative expenses also rose by 15% to $22.05 million, primarily due to costs associated with legal matters and intellectual property defense.

AbCellera's operational metrics indicate a growing pipeline, with a cumulative total of 103 partner-initiated programs as of September 30, 2025, an increase from 95 programs a year earlier. The number of molecules in clinical trials also rose to 18, up from 14 in the previous year. The company has made significant strides in advancing its internal programs, including the initiation of Phase 1 clinical trials for two therapies, ABCL635 and ABCL575, which received regulatory approval in May 2025.

The company’s cash and cash equivalents, along with marketable securities, totaled $495.67 million as of September 30, 2025, a decrease from $625.61 million at the end of 2024. This decline was primarily due to cash used in operations and investments in research and development activities. AbCellera anticipates that its existing liquidity will be sufficient to meet its operational and capital needs for at least the next 36 months, as it continues to focus on expanding its capabilities and advancing its pipeline of antibody-based therapies. The company remains committed to its strategic goals, including enhancing its discovery and development capabilities and pursuing partnerships to maximize the potential of its antibody therapeutics.